A response from A. Carvajal, S. Ortega and colleagues to a letter to the editor on their article "Heart Rhythm Disturbances Associated With Rupatadine: A Case Series From the Spanish and Portuguese Pharmacovigilance Systems," published in a previous issue, is presented.